2 Paediatrics Academic Clinical Programme, Duke-NUS Medical School, Singapore 3 Paediatrics Academic Clinical Programme, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore ...

Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.

The Post-Bariatric Hypoglycemia market growth is driven by factors like increase in the prevalence of Post-Bariatric ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

A replay of both events will be available in the Investors section on the Company's website at www.soleno.life.

After hours: February 21 at 4:50:40 PM EST Loading Chart for SLNO ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have received a consensus rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Five ...

Figure 1: Mitochondrial involvement in cell death. Mitochondria are organelles with two well-defined compartments: the matrix, surrounded by the inner membrane (IM), and the intermembrane space ...

Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. Receive News & Ratings ...

The biotech’s lead drug candidate is in Phase 3 testing in Prader-Willi syndrome, a genetic disorder that causes persistent hunger leading to overeating.

1 College of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China 2 Department of Endocrine and Metabolic Disease, The Affiliated Hospital to Changchun University of ...